Artivion, Inc. (NYSE:AORT) CAO Amy Horton Sells 4,329 Shares

Artivion, Inc. (NYSE:AORT) CAO Amy Horton sold 4,329 shares of the company’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $29.66, for a total value of $128,398.14. Following the transaction, the chief accounting officer now directly owns 135,660 shares in the company, valued at $4,023,675.60. This represents a 3.09 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Amy Horton also recently made the following trade(s):

• On Tuesday, October 1st, Amy Horton sold 12,430 shares of Artivion stock. The stock was sold at an average price of $26.18, for a total value of $325,417.40.

Artivion Stock Up 2.9 %

AORT stock opened at $29.83 on Wednesday. The company has a market capitalization of $1.25 billion, a P/E ratio of -1,491.50 and a beta of 1.75. Artivion, Inc. has a 12 month low of $16.48 and a 12 month high of $30.22. The firm’s fifty day simple moving average is $27.51 and its 200-day simple moving average is $26.11. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Oppenheimer lifted their target price on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Stifel Nicolaus boosted their price objective on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. Needham & Company LLC restated a “buy” rating and issued a $34.00 target price on shares of Artivion in a research note on Monday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price target on shares of Artivion in a research report on Tuesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $31.80.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AORT. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Artivion by 58.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after buying an additional 125,668 shares during the last quarter. Centiva Capital LP purchased a new position in Artivion during the third quarter valued at approximately $565,000. Sio Capital Management LLC acquired a new position in Artivion in the third quarter valued at approximately $3,226,000. First Eagle Investment Management LLC boosted its position in Artivion by 4.9% in the 2nd quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company’s stock worth $15,342,000 after purchasing an additional 27,906 shares in the last quarter. Finally, Tidal Investments LLC acquired a new stake in shares of Artivion during the 1st quarter worth approximately $257,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.